Bionik Laboratories (BNKL) 10-Q 14 Aug 17 2018 Q1 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	3 Months Ended
	Jun. 30, 2017	Aug. 10, 2017
Document Information [Line Items]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Jun. 30, 2017
Document Fiscal Year Focus	2,018
Document Fiscal Period Focus	Q1
Entity Registrant Name	Bionik Laboratories Corp.
Entity Central Index Key	1,508,381
Current Fiscal Year End Date	--03-31
Entity Filer Category	Smaller Reporting Company
Trading Symbol	BNKL
Entity Common Stock, Shares Outstanding		53,885,279

Condensed Consolidated Interim

Condensed Consolidated Interim Balance Sheets - USD ($)	Jun. 30, 2017	Mar. 31, 2017
Current
Cash and cash equivalents	$ 846,431	$ 543,650
Accounts receivable	134,926	383,903
Prepaid expenses and other receivables (Note 4)	172,051	228,047
Inventories (Note 5)	255,546	228,249
Due from related parties (Note 8)(a)	19,366	18,731
Total Current Assets	1,428,320	1,402,580
Equipment (Note 6)	218,469	227,421
Technology and other assets (Note 3)	4,937,675	5,030,624
Goodwill (Note 3)	22,308,275	22,308,275
Total Assets	28,892,739	28,968,900
Current
Accounts Payable (Notes 8(b) and 13)	890,624	784,726
Accrued liabilities (Notes 7 and 8(b))	1,223,130	1,228,657
Customer advances	229,862	121,562
Demand Loans (Note 7)	332,941	330,600
Promissory Notes payable (Note 7)	241,700	236,548
Convertible Loans (Note 7)	2,581,510	2,017,488
Deferred revenue	106,609	98,624
Warrant Derivative Liability (Note 11)	759,714	959,600
Total Current Liabilities	6,366,090	5,777,805
Shareholders’ Equity
Common Shares, par value $0.001; Authorized - 150,000,000 (March 31, 2017 - 150,000,000); Issued and outstanding 53,885,279 and 47,909,336 Exchangeable Shares (March 31, 2017 - 48,885,107 and 47,909,336 Exchangeable Shares) (Note 9)	101,794	96,794
Additional paid in capital	40,216,582	38,640,706
Deficit	(17,833,876)	(15,588,554)
Accumulated other comprehensive income	42,149	42,149
Total Shareholders’ Equity	22,526,649	23,191,095
Total Liabilities and Shareholders’ Equity	28,892,739	28,968,900
Special Voting Preferred Stock [Member]
Shareholders’ Equity
Preferred Stock, par value $0.001; Authorized 10,000,000 Special Voting Preferred Stock, par value $0.001; Authorized; Issued and outstanding - 1 (March 31, 2017 - 1)	$ 0	$ 0

Condensed Consolidated Interim3

Condensed Consolidated Interim Balance Sheets [Parenthetical] - $ / shares	Jun. 30, 2017	Mar. 31, 2017
Preferred Stock, Par Value (in dollars per share)	$ 0.001	$ 0.001
Preferred Stock, Shares Authorized	10,000,000	10,000,000
Common Stock, Par Value (in dollars per share)	$ 0.001	$ 0.001
Common Stock, Shares Authorized	150,000,000	150,000,000
Common Stock, Shares, Issued	53,885,279	48,885,107
Common Stock, Shares, Outstanding	53,885,279	48,885,107
Common Stock, Other Shares, Outstanding	47,909,336	47,909,336
Special Voting Preferred Stock [Member]
Preferred Stock, Par Value (in dollars per share)	$ 0.001	$ 0.001
Preferred Stock, Shares Issued	1	1
Preferred Stock, Shares Outstanding	1	1

Condensed Consolidated Interim4

Condensed Consolidated Interim Statements of Operations and Comprehensive Loss - USD ($)	3 Months Ended
	Jun. 30, 2017	Jun. 30, 2016
Sales	$ 87,520	$ 164,191
Cost of Sales	29,300	58,875
Gross Margin	58,220	105,316
Operating expenses
Sales and marketing	445,525	82,198
Research and development	685,909	417,790
General and administrative	627,606	1,303,614
Share-based compensation expense (Notes 9(c) and 10)	251,048	219,248
Amortization (Note 3)	92,949	0
Depreciation (Note 6)	24,552	10,163
Total operating expenses	2,127,589	2,033,013
Other expenses (income)
Foreign exchange	98,561	0
Interest expense (Note 7)	72,766	15,234
Other income	(178)	(11,218)
Change in fair value of warrant derivative liability (Note 11)	4,804	391,059
Total other expenses (income)	175,953	395,075
Net loss and comprehensive loss for the period	$ (2,245,322)	$ (2,322,772)
Loss per share - basic and diluted	$ (0.02)	$ (0.03)
Weighted average number of shares outstanding - basic and diluted	96,959,284	82,050,549

Condensed Consolidated Interim5

Condensed Consolidated Interim Statements of Changes in Shareholders’ Equity (Deficiency) - USD ($)	Total	Special Voting Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Deficit [Member]	Comprehensive Income [Member]
Opening Balance at Mar. 31, 2016	$ 263,906	$ 0	$ 72,591	$ 11,801,146	$ (11,651,980)	$ 42,149
Opening Balance (in shares) at Mar. 31, 2016		1	72,591,292
Shares issued to acquire IMT	23,177,000	$ 0	$ 23,650	23,153,350	0	0
Shares issued to acquire IMT (in shares)		0	23,650,000
Stock compensation acquired	2,582,890	$ 0	$ 0	2,582,890	0	0
Options exercised	18,166	$ 0	$ 110	18,056	0	0
Options exercised (in shares)		0	110,096
Cashless exercise of warrants	$ 43,562	$ 0	$ 51	43,511	0	0
Cashless exercise of warrants (in shares)	51,249	0	51,249
Warrants exercised	$ 40,195	$ 0	$ 175	40,020	0	0
Warrants exercised (in shares)		0	174,759
Share compensation expense	1,001,950	$ 0	$ 217	1,001,733	0	0
Share compensation expense (in shares)		0	217,047
Net loss for the period	(3,936,574)	$ 0	$ 0	0	(3,936,574)	0
Closing Balance at Mar. 31, 2017	23,191,095	$ 0	$ 96,794	38,640,706	(15,588,554)	42,149
Closing Balance (in shares) at Mar. 31, 2017		1	96,794,443
Warrants exercised	1,125,038	$ 0	$ 5,000	1,120,038	0	0
Warrants exercised (in shares)		0	5,000,172
Share compensation expense	251,048	$ 0	$ 0	251,048	0	0
Share compensation expense (in shares)		0	0
Fair value adjustment for warrants exercised	204,790	$ 0	$ 0	204,790	0	0
Net loss for the period	(2,245,322)	0	0	0	(2,245,322)	0
Closing Balance at Jun. 30, 2017	$ 22,526,649	$ 0	$ 101,794	$ 40,216,582	$ (17,833,876)	$ 42,149
Closing Balance (in shares) at Jun. 30, 2017		1	101,794,615

Condensed Consolidated Interim6

Condensed Consolidated Interim Statements of Cash Flows - USD ($)	1 Months Ended	3 Months Ended
	Apr. 21, 2016	Jun. 30, 2017	Jun. 30, 2016
Operating activities
Net loss for the period		$ (2,245,322)	$ (2,322,772)
Adjustment for items not affecting cash
Depreciation		24,552	10,163
Amortization		92,949	0
Interest expense		72,766	15,234
Share based compensation expense		251,048	159,818
Shares issued for services		0	59,500
Change in fair value of warrant derivative liability		4,804	391,059
Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities		(1,799,203)	(1,686,998)
Changes in non-cash working capital items
Accounts receivable		248,977	(113,870)
Prepaid expenses and other receivables		55,996	60,142
Due from related parties		(635)	(178)
Inventories		(27,297)	(71,380)
Accounts payable		104,648	(703,526)
Accrued liabilities		(5,428)	(382,629)
Customer advances		108,300	0
Deferred revenue		7,985	0
Net cash used in operating activities		(1,306,657)	(2,898,439)
Investing activities
Acquisition of equipment		(15,600)	0
Net cash used in investing activities		(15,600)	0
Financing activities
Proceeds from convertible loans		500,000	0
Proceeds on exercise of warrants		1,125,038	0
Cash acquired on acquisition	$ 266,635	0	266,635
Net cash provided by financing activities		1,625,038	266,635
Net (increase) decrease in cash and cash equivalents for the period		302,781	(2,631,804)
Cash and cash equivalents, beginning of period	5,381,757	543,650	5,381,757
Cash and cash equivalents, end of period		846,431	$ 2,749,953
Assets acquired and liabilities assumed as at April 21, 2016:
Current assets, including cash of $266,635	478,843
Equipment	59,749
Intangible assets	5,580,704	$ 5,580,704
Goodwill	22,308,275
Accounts payable	(241,299)
Accrued liabilities	(361,029)
Customer deposits	(86,487)
Demand notes payable	(324,894)
Promissory Notes payable	(217,808)
Bionik advance	(1,436,164)
Non-cash consideration	$ 25,759,890

Condensed Consolidated Interim7

Condensed Consolidated Interim Statements of Cash Flows [Parenthetical] - USD ($)	1 Months Ended	3 Months Ended
	Apr. 21, 2016	Jun. 30, 2017	Jun. 30, 2016
Cash Acquired from Acquisition	$ 266,635	$ 0	$ 266,635

NATURE OF OPERATIONS

NATURE OF OPERATIONS	3 Months Ended
	Jun. 30, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Nature of Operations [Text Block]	1. NATURE OF OPERATIONS The Company and its Operations Bionik Laboratories Corp. (formerly Drywave Technologies Inc., the “Company” or “Bionik”) was incorporated on January 8, 2010 in the State of Colorado as Strategic Dental Management Corp. On July 16, 2013, the Company changed its name to Drywave Technologies Inc. (“Drywave”) and its state of incorporation from Colorado to Delaware. Effective February 13, 2015, the Company changed its name to Bionik Laboratories Corp. and reduced the authorized number of shares of common stock from 200,000,000 150,000,000 On February 26, 2015, the Company entered into a Share Exchange Agreement and related transactions whereby it acquired Bionik Laboratories Inc., a Canadian Corporation (Bionik Canada and Bionik Canada issued 50,000,000 3.14 100 As a result of the shareholders of Bionik Canada having a controlling interest in the Company subsequent to the Merger, for accounting purposes the Merger does not constitute a business combination. The transaction has been accounted for as a recapitalization of the Company with Bionik Canada being the accounting acquirer even though the legal acquirer is Bionik, accordingly, the historic financial statements of Bionik Canada are presented as the comparative balances for the period prior to the Merger. References to the Company refer to the Company and its wholly owned subsidiaries, Bionik Acquisition Inc. and Bionik Canada. References to Drywave relate to the Company prior to the Merger. On April 21, 2016, the Company acquired all of the outstanding shares and, accordingly, all assets and liabilities of Interactive Motion Technologies, Inc. (“IMT”), a Boston, Massachusetts-based global pioneer and leader in providing effective robotic products for neurorehabilitation, pursuant to an Agreement and Plan of Merger (the “Merger Agreement”) dated March 1, 2016, with IMT, Hermano Igo Krebs, and Bionik Mergerco Inc., a Massachusetts corporation and the Company’s wholly owned subsidiary (Bionik Mergeco). The merger agreement provided for the merger of Bionik Mergerco with and into IMT, with IMT surviving the merger as the Company’s wholly owned subsidiary. In return for acquiring IMT, IMT shareholders received an aggregate of 23,650,000 The Company is a global pioneering robotics company focused on providing rehabilitation solutions to individuals with neurological disorders, specializing in designing, developing and commercializing cost-effective physical rehabilitation technologies, prosthetics, and assisted robotic products. The Company strives to innovate and build devices that can rehabilitate and improve an individual’s health, comfort, accessibility and quality of life through the use of advanced algorithms and sensing technologies that anticipate a user’s every move. The unaudited condensed consolidated interim financial statements consolidate the Company and its wholly owned subsidiaries Bionik Canada, Bionik Acquisition Inc. and Bionik, Inc. (the former IMT) since its acquisition on April 21, 2016. These unaudited condensed consolidated interim financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“US GAAP”), which contemplates continuation of the Company as a going concern, which assumes the realization of assets and satisfaction of liabilities and commitments in the normal course of business. The Company’s principal offices are located at 483 Bay Street, N105, Toronto, Ontario, Canada M5G 2C9 and its U.S. address is 80 Coolidge Hill Road, Watertown, MA. USA 02472. Going Concern As at June 30, 2017, the Company had a working capital deficit of $ 4,937,770 4,375,225 17,833,876 15,588,554 2,245,322 2,322,772 There is no certainty that the Company will be successful in generating sufficient cash flow from operations or achieving and maintaining profitable operations in the future to enable it to meet its obligations as they come due and consequently continue as a going concern. The Company will require additional financing this year to fund its operations and it is currently working on securing this funding through corporate collaborations, public or private equity offerings or debt financings. Sales of additional equity securities by the Company would result in the dilution of the interests of existing stockholders. There can be no assurance that financing will be available when required. In the event that the necessary additional financing is not obtained, the Company would reduce its discretionary overhead costs substantial or otherwise curtail operations. The Company expects the forgoing, or a combination thereof, to meet the Company’s anticipated cash requirements for the next 12 months; however, these conditions raise substantial doubt about the Company’s ability to continue as a going concern. The accompanying condensed consolidated interim financial statements do not include any adjustments to reflect the possible future effects on recoverability and reclassification of assets or the amounts and classification of liabilities that may result from the outcome of this uncertainty. The condensed consolidated interim financial statements do not include any adjustments related to the recoverability and classification of the recorded asset amounts or the amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern. All adjustments, consisting only of normal recurring items, considered necessary for fair presentation have been included in these condensed consolidated interim financial statements.

SIGNIFICANT ACCOUNTING POLICIES

SIGNIFICANT ACCOUNTING POLICIES	3 Months Ended
	Jun. 30, 2017
Accounting Policies [Abstract]
Significant Accounting Policies [Text Block]	2. SIGNIFICANT ACCOUNTING POLICIES These unaudited condensed consolidated interim financial statements have been prepared on the same basis as the annual audited financial statements of the Company and should be read in conjunction with those annual audited financial statements filed on Form 10-K for the year ended March 31, 2017. In the opinion of management, these unaudited condensed consolidated interim financial statements reflect adjustments, necessary to present fairly the Company’s financial position, results of operations and cash flows for the periods shown. The results of operations for such periods are not necessarily indicative of the results expected for a full year or for any future period. In May 2014, the FASB issued ASU No. 2014-09, “Revenue from Contracts with Customers (Topic 606)”. The standard outlines a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and supersedes most current revenue recognition guidance. The accounting standard is effective for annual reporting periods (including interim reporting periods within those periods) beginning after December 15, 2017. Early adoption is not permitted. The impact on the condensed consolidated interim In August 2014, the FASB issued a new financial accounting standard on going concern, ASU No. 2014-15, “Presentation of Financial Statements – Going Concern (Sub-Topic 205-40): Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern.” The standard provides guidance about management’s responsibility to evaluate whether there is a substantial doubt about the organization’s ability to continue as a going concern. The amendments in this Update apply to all companies. They become effective in the annual period ending after December 15, 2016, with early application permitted. The Company has adopted this ASU No. 2014-15 as at and for the year ended March 31, 2017. There was no material effect on the condensed consolidated interim In November 2015, the FASB issued ASU No. 2015-17, “Balance Sheet Classification of Deferred Taxes,” which requires that deferred tax liabilities and assets be classified on our Consolidated Balance Sheets as noncurrent based on an analysis of each taxpaying component within a jurisdiction. ASU No. 2015-17 is effective for the fiscal year commencing after December 15, 2017. The Company does not anticipate that the adoption of ASU No. 2015-17 will have a material effect on the condensed consolidated interim In January 2016, the FASB issued ASU No. 2016-01 Financial Instruments - Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities. The updates makes several modifications to Subtopic 825-10, including the elimination of the available-for-sale classification of equity investments, and it requires equity investments with readily determinable fair values to be measured at fair value with changes in fair value recognized in operations. The update is effective for fiscal years beginning after December 2017. The Company is still assessing the impact that the adoption of ASU 2016-01 will have on the condensed consolidated interim In February 2016, the FASB issued ASU 2016-02, Leases. This update requires organizations that lease assets to recognize on the balance sheet the assets and liabilities for the rights and obligations created by those leases. The new guidance will also require additional disclosure about the amount, timing and uncertainty of cash flows arising from leases. The provisions of this update are effective for annual and interim periods beginning after December 15, 2018. The Company is still assessing the impact that the adoption of ASU 2016-02 will have on the condensed consolidated interim In March 2016, the FASB issued ASU 2016-09, “Compensation - Stock Compensation: Improvements to Employee Share-Based Payment Accounting”. Several aspects of the accounting for share-based payment award transaction are simplified, including (a) income tax consequences; (b) classification of awards as either equity or liabilities; and (c) classification on the statement of cash flows. The amendments are effective for annual periods beginning after December 15, 2016, and interim periods within those annual periods. The Company has adopted this policy during the period and there was no impact on the condensed consolidated interim financial statements. In August 2016, the FASB issued ASU 2016-15, “Statement of Cash Flows: Classification of Certain Cash Receipts and Cash Payments”. This ASU provides eight targeted changes to how cash receipts and cash payments are presented and classified in the statement of cash flows. ASU 2016-15 is effective for the fiscal year commencing after December 15, 2017. The Company is still assessing the impact that the adoption of ASU 2016-15 will have on the condensed consolidated interim In January 2017, the FASB issued ASU 2017-01, “Business Combinations: Clarifying the definition of a Business” which amends the current definition of a business. Under ASU 2017-01, to be considered a business, an acquisition would have to include an input and a substantive process that together significantly contributes to the ability to create outputs. ASU 2017-01 further states that when substantially all of the fair value of gross assets acquitted is concentrated in a single asset (or a group of similar assets), the assets acquired would not represent a business. The new guidance also narrows the definition of the term “outputs” to be consistent with how it described in Topic 606, Revenue from Contracts with Customers. The changes to the definition of a business will likely result in more acquisitions being accounted for as asset acquisitions. ASU 2017-01 is effective for acquisitions commencing on or after June 30, 2019, with early adoption permitted. Adoption of this guidance will be applied prospectively on or after the effective date. In January 2017, the FASB issued ASU 2017-04, “Intangibles – Goodwill and Other” ASU 2017-04 simplifies the accounting for goodwill impairment by eliminating Step 2 of the current goodwill impairment test, which required a hypothetical purchase price allocation. Goodwill impairment will now be the amount by which the reporting unit’s carrying value exceeds its fair value, limited to the carrying value of the goodwill. ASU 2017-04 is effective for financial statements issued for fiscal years, and interim periods beginning after December 15, 2019. The Company recognizes revenue from product sales when persuasive evidence of an agreement with customer exists, products are shipped or title passes pursuant to the terms of the agreement, the amount due from the customer is fixed or determinable, collectability is reasonably assured, and there are no significant future performance obligation. Deposits are carried as liabilities until the requirements for revenue recognition are met. The Company’s derivative warrant instruments are measured at fair value using a simulation model which takes into account, as of the valuation date, factors including the current exercise price, the expected life of the warrant, the current price of the underlying stock, its expected volatility, holding cost and the risk-free interest rate for the term of the warrant (Note 11). The warrant derivative liability is revalued at each reporting period and changes in fair value are recognized in the condensed consolidated interim statements of operations and comprehensive loss under the caption “Change in fair value of warrant derivative liability”. The selection of the appropriate valuation model and the inputs and assumptions that are required to determine the valuation requires significant judgment and requires management to make estimates and assumptions that affect the reported amount of the related liability and reported amounts of the change in fair value. Actual results could differ from those estimates, and changes in these estimates are recorded when known. As the derivative warrant liability is required to be measured at fair value at each reporting date it is reasonably possible that these estimates and assumptions could change in the near term. The Company provides a one-year warranty as part of its normal sales offering. When products are sold, the Company provides warranty reserves, which, based on the historical experience of the Company are sufficient to cover warranty claims. Accrued warranty reserves are included in accrued liabilities on the balance sheet amounted to $ 64,957 15,190 The functional currency of the Company and its wholly owned subsidiaries is the U.S. dollar. Transactions denominated in a currency other than the functional currency are recorded on initial recognition at the exchange rate at the date of the transaction. After initial recognition, monetary assets and liabilities denominated in foreign currency are translated at the end of each reporting period into the functional currency at the exchange rate at that date. Exchange differences are recognized in profit or loss. Non-monetary assets and liabilities measured at cost are translated at the exchange rate at the date of the transaction. ASC Topic 820 defines fair value, establishes a framework for measuring fair value, and expands disclosures about fair value measurements. Included in the ASC Topic 820 framework is a three level valuation inputs hierarchy with Level 1 being inputs and transactions that can be effectively fully observed by market participants spanning to Level 3 where estimates are unobservable by market participants outside of the Company and must be estimated using assumptions developed by the Company. The Company discloses the lowest level input significant to each category of asset or liability valued within the scope of ASC Topic 820 and the valuation method as exchange, income or use. The Company uses inputs which are as observable as possible and the methods most applicable to the specific situation of each company or valued item. The carrying amounts reported in the balance sheets for cash and cash equivalents, accounts receivable, other receivables, accounts payable and accrued liabilities, due from related parties approximate fair value because of the short period of time between the origination of such instruments and their expected realization and their current market rates of interest. Per ASC Topic 820 framework these are considered Level 2 inputs where inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices in active markets for similar assets or liabilities, quoted prices for identical or similar assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. As at June 30, 2017 and March 31, 2017, the Company’s warrant derivative liability was measured at fair value at each reporting period using a simulation model based on Level 3 inputs. The Company’s policy is to recognize transfers into and out of Level 3 as of the date of the event or change in the circumstances that caused the transfer. There were no such transfers during the period.

ACQUISITION

ACQUISITION	3 Months Ended
	Jun. 30, 2017
Business Combinations [Abstract]
Business Combination Disclosure [Text Block]	3. ACQUISITION On April 21, 2016, the Company acquired 100 23,650,000 Bionik also assumed each of the 3,895,000 3,000,000 1,000,000 0.25 1,000,000 0.95 1,000,000 1.05 2,582,890 As a result of the acquisition of IMT, the Company acquired assets including three licensed patents, two license agreements, three FDA listed products, an FDA inspected manufacturing facility, extensive clinical and sales data, and international distributors. The Company retained an independent valuator to determine the purchase price allocation, which reflects the allocation of assets and goodwill. As at April 21, 2016 $ Fair value of 23,650,000 shares of common stock (a) 23,177,000 Fair value of vested stock options (b) 2,582,890 Allocation of purchase price: 25,759,890 Cash and cash equivalents 266,635 Accounts receivable 6,490 Inventories 188,879 Prepaid expenses and other current assets 16,839 Equipment 59,749 Liabilities assumed: Accounts payable (241,299) Accrued liabilities (361,029) Customer deposits (86,487) Demand notes payable (324,894) Promissory notes payable (217,808) Bionik advance (c) (1,436,164) Net assets acquired (2,129,089) Patents and exclusive License Agreement 1,306,031 Trademark 2,505,907 Customer relationships 1,431,680 Non compete agreement 61,366 Assembled Workforce 275,720 Goodwill 22,308,275 25,759,890 (a) The fair value of common stock was based on $ 0.98 (b) The fair value of the vested stock options was determined using the Black Scholes option pricing model with the following key assumptions: a risk free rate of 1.59 0 114 (c) Included in the net assets acquired was a loan issued to IMT in the amount of $ 300,000 6 200,000 Intangible Amortization Expense March Value at March Expense June Value at June assets acquired period (years) Value acquired 31, 2017 31, 2017 30, 2017 30, 2017 $ $ $ $ $ Patents and exclusive License Agreement 9.74 1,306,031 126,375 1,179,656 33,559 1,146,097 Trademark Indefinite 2,505,907 - 2,505,907 - 2,505,907 Customer relationships 10 1,431,680 134,931 1,296,749 35,830 1,260,919 Non compete agreement 2 61,366 28,918 32,448 7,696 24,752 Assembled Workforce 1 275,720 259,856 15,864 15,864 - 5,580,704 550,080 5,030,624 92,949 4,937,675

PREPAID EXPENSES AND OTHER RECE

PREPAID EXPENSES AND OTHER RECEIVABLES	3 Months Ended
	Jun. 30, 2017
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Prepaid Expense And Other Receivables [Text Block]	4. PREPAID EXPENSES AND OTHER RECEIVABLES June 30, March 31, 2017 2017 $ $ Prepaid expenses and sundry receivables 76,828 68,484 Prepaid insurance 81,166 136,896 Sales taxes receivable (i) 14,057 22,667 172,051 228,047 (i) Sales tax receivable represents net harmonized sales taxes (HST) input tax credits receivable from the Government of Canada.

INVENTORIES

INVENTORIES	3 Months Ended
	Jun. 30, 2017
Inventory Disclosure [Abstract]
Inventory Disclosure [Text Block]	5. INVENTORIES June 30, March 31, 2017 2017 $ $ Raw materials 137,783 119,985 Work in progress 59,163 108,264 Finished Goods 58,600 - 255,546 228,249

EQUIPMENT

EQUIPMENT	3 Months Ended
	Jun. 30, 2017
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment Disclosure [Text Block]	6. EQUIPMENT June 30, 2017 March 31, 2017 Accumulated Accumulated Cost Depreciation Net Cost Depreciation Net $ $ $ $ $ $ Computers and electronics 250,538 209,805 40,733 250,538 204,258 46,280 Furniture and fixtures 36,795 26,623 10,172 36,795 26,096 10,699 Demonstration equipment 200,186 61,221 138,965 184,586 44,420 140,166 Manufacturing equipment 88,742 85,166 3,576 88,742 84,982 3,760 Tools and parts 11,422 4,813 6,609 11,422 4,472 6,950 Assets under capital lease 23,019 4,605 18,414 23,019 3,453 19,566 610,702 392,233 218,469 595,102 367,681 227,421 Equipment is recorded at cost less accumulated depreciation. Depreciation expense during the period ended June 30, 2017 was $ 24,552 10,163

NOTES PAYABLE

NOTES PAYABLE	3 Months Ended
	Jun. 30, 2017
Debt Disclosure [Abstract]
Debt Disclosure [Text Block]	7. NOTES PAYABLE Demand Notes payable The Company has outstanding notes payable (“Notes”) of $ 330,600 3.50 15 151,737 150,689 Balance, March 31, 2017 330,600 Accrued interest 2,341 Balance, June 30, 2017 $ 332,941 Interest expense incurred on the Notes totaled $ 2,341 3,325 Promissory Notes payable In February 2014, the Company borrowed $ 200,000 10 5,152 3,890 41,700 Balance, March 31, 2017 236,548 Accrued interest 5,152 Balance, June 30, 2017 $ 241,700 Convertible Loans Payable (a) In December 2016, several shareholders of the Company agreed to advance the Company $ 1,500,000 500,000 500,000 500,000 2,000,000 17,488 60,493 The convertible loans contain the following terms: convertible at the option of the holder at the price of the equity financing or payable on demand upon the completion of an equity financing greater than $5,000,000; automatically convertible at the price of the equity financing upon completion of an equity financing between $3,500,000 and $5,000,000 Prior to their maturity, the convertible loans were extended to November 15, 2017 12 10 300,000 (b) In May 2017, the Company’s Chinese joint venture partners loaned the Company $500,000 with an interest rate of 8% convertible into the Company’s common shares upon a capital raise (“Qualified Financing”) where gross proceeds exceed $3,000,000 at the lesser of $0.50 and the quotient of the outstanding balance on conversion date by the price of the Qualified Financing. Additionally, the holders are entitled to warrants equaling 25% of the number of conversion shares to be issued at conversion. 3,529

RELATED PARTY TRANSACTIONS AND

RELATED PARTY TRANSACTIONS AND BALANCES	3 Months Ended
	Jun. 30, 2017
Related Party Transactions [Abstract]
Related Party Transactions Disclosure [Text Block]	8. RELATED PARTY TRANSACTIONS AND BALANCES a) Due from related parties As of June 30, 2017 there was an outstanding loan to the Chief Technology Officer and director of the Company for $ 19,366 18,731 1 635 707 b) Accounts payable and accrued liabilities As at June 30, 2017, $ 8,882 1,118 23,565 16,941 1,946 In connection with the acquisition of IMT, the Company acquired a license agreement dated June 8, 2009, pursuant to which the Company pays the licensors an aggregate royalty of 1 As at June 30, 2017, $ 120,000 120,000 15 33,000 As at the effective date of the merger pursuant to the Merger Agreement, a former officer and director received an aggregate of 5,190,376 360,231

SHARE CAPITAL

SHARE CAPITAL	3 Months Ended
	Jun. 30, 2017
Stockholders' Equity Note [Abstract]
Stockholders' Equity Note Disclosure [Text Block]	9. SHARE CAPITAL June 30, 2017 March 31, 2017 Number of Number of shares $ shares $ Exchangeable Shares: Balance beginning of period/year 47,909,336 47,910 50,000,000 50,000 Converted into common shares - - (2,090,664) (2,090) Balance at the end of period/year 47,909,336 47,910 47,909,336 47,910 Common Shares Balance at beginning of the period 48,885,107 48,884 22,591,292 22,591 Shares issued on acquisition (Note 3) - - 23,650,000 23,650 Shares issued to exchangeable shares - - 2,090,664 2,090 Shares issued for services - - 217,047 217 Options exercised - - 110,096 110 Warrants exercise (a) 5,000,172 5,000 174,759 175 Cashless exercise of warrants - - 51,249 51 Balance at end of the period 53,885,279 53,884 48,885,107 48,884 TOTAL COMMON SHARES 101,794,615 101,794 96,794,443 96,794 (a) During the three month period ended June 30, 2017, the Company consummated an offer to amend and exercise to its warrant holders, enabling them to exercise their outstanding warrants for $ 0.25 5,000,172 1,125,038 (b) During the three month period ended June 30, 2016, 51,249 262,045 0.80 43,562 (c) The Company issued 70,000 59,500 Special Voting Preferred Share In connection with the Merger (Note 1), on February 26, 2015, the Company entered into a voting and exchange trust agreement (the “Trust Agreement”). Pursuant to the Trust Agreement, the Company issued one share of the Special Voting Preferred Stock, par value $0.001 per share, of the Company (the Special Voting Preferred Share”) to the Trustee, and the parties created a trust for the Trustee to hold the Special Voting Preferred Share for the benefit of the holders of the Exchangeable Shares (the “Beneficiaries”). Pursuant to the Trust Agreement, the Beneficiaries have voting rights in the Company equivalent to what they would have had, had they received shares of common stock in the same amount as the Exchangeable Shares held by the Beneficiaries. In connection with the Merger and the Trust Agreement, effective February 20, 2015, the Company filed a certificate of designation of the Special Voting Preferred Share (the “Special Voting Certificate of Designation”) with the Delaware Secretary of State. Pursuant to the Special Voting Certificate of Designation, one share of the Company’s blank check preferred stock was designated as the Special Voting Preferred Share. The Special Voting Preferred Share entitles the Trustee to exercise the number of votes equal to the number of Exchangeable Shares outstanding on a one-for-one basis during the term of the Trust Agreement. The Special Voting Preferred Share is not entitled to receive any dividends or to receive any assets of the Company upon liquidation, and is not convertible into common shares of the Company. The voting rights of the Special Voting Preferred Share will terminate pursuant to and in accordance with the Trust Agreement. The Special Voting Preferred Share will be automatically cancelled at such time as no Exchangeable Shares are held by a Beneficiary.

STOCK OPTIONS

STOCK OPTIONS	3 Months Ended
	Jun. 30, 2017
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Disclosure of Compensation Related Costs, Share-based Payments [Text Block]	10. STOCK OPTIONS The purpose of the Company’s equity incentive plan, is to attract, retain and motivate persons of training, experience and leadership to the Company, including their directors, officers and employees, and to advance the interests of the Company by providing such persons with the opportunity, through share options, to acquire an increased proprietary interest in the Company. Options or other securities may be granted in respect of authorized and unissued shares, provided that the aggregate number of shares reserved for issuance upon the exercise of all options or other securities granted under the Plan shall not exceed 15% of the shares of common stock and Exchangeable Shares issued and outstanding (determined as of January 1 of each year). Optioned shares in respect of which options are not exercised shall be available for subsequent options. On April 11, 2014 and June 20, 2014, the Company issued 657,430 264,230 0.165 0.23 125,824 531,606 264,230 230,930 118,957 62,912 On July 1, 2014, the Company issued 2,972,592 0.23 7 1,259,487 990,864 On February 17, 2015, the Company granted 314,560 0.23 136,613 110,100 On November 24, 2015, the Company granted 650,000 694,384 250,000 35,609 On December 14, 2015, the Company granted 2,495,000 1,260,437 25,000 40,000 100,289 On April 21, 2016, the Company granted 3,000,000 3,895,000 1,000,000 0.25 1,000,000 0.95 1,000,000 1.05 2,582,890 10,169 On April 26, 2016, the Company granted 250,000 1.00 213,750 17,813 On August 8, 2016, the Company granted 750,000 1.00 652,068 54,339 On February 6, 2017, the Company granted 400,000 0.70 245,200 20,433 On February 13, 2017, the Company granted 250,000 0.68 148,750 12,396 During the quarter ended June 30, 2017, the Company recorded $ 251,048 159,818 Exercise Price ($) Number of Options Expiry Date Exercisable Options 0.165 264,230 April 1, 2021 264,230 0.23 97,514 June 20, 2021 97,514 0.23 1,981,728 July 1, 2021 1,981,728 0.23 204,471 February 17, 2022 204,471 1.22 400,000 November 24, 2022 133,333 1.00 2,316,667 December 14, 2022 809,994 0.95 111,937 March 28, 2023 111,937 1.05 433,027 March 28, 2023 433,027 1.00 250,000 April 26, 2023 - 1.00 750,000 August 8, 2023 - 0.70 400,000 February 6, 2024 - 0.68 250,000 February 13, 2024 - 0.95 31,620 March 3, 2024 31,620 1.05 122,324 March 3, 2024 122,324 0.95 15,810 March 14, 2024 15,810 1.05 61,162 March 14, 2024 61,162 0.95 82,213 September 30, 2024 82,213 1.05 318,042 September 30, 2024 318,042 0.95 7,431 June 2, 2025 7,431 1.05 28,747 June 2, 2025 28,747 0.25 906,077 July 28, 2025 906,077 0.95 671,859 July 29, 2025 671,859 0.25 66,298 December 30, 2025 53,909 0.95 49,160 December 30, 2025 27,261 9,820,317 6,362,689 The weighted-average remaining contractual term of the outstanding options was 5.81 5.12 5.70 6.02

WARRANTS

WARRANTS	3 Months Ended
	Jun. 30, 2017
Warrants and Rights Note Disclosure [Abstract]
Shareholders Equity And Share Based Payments Stock Warrant [Text Block]	11. WARRANTS Weighted-Average Number of Warrants Exercise Price ($) Outstanding and exercisable, March 31, 2015 10,823,450 1.35 Issued 7,225,625 1.35 Exercised (148,787) (0.80) Outstanding and exercisable, March 31, 2016 17,900,288 1.35 Exercised (262,045) (0.80) Outstanding and exercisable, March 31, 2017 17,638,243 1.35 Exercised (5,000,172) 0.25 Dilution warrants issued to $0.80 warrant holders 83,752 0.749 Dilution warrants issued to $1.40 warrant holders 941,191 1.2933 Outstanding at June 30, 2017 13,663,014 1.241 During the three months period ended June 30, 2017, the Company consummated an offer to amend and exercise its outstanding warrants, enabling the holders of the warrants to exercise such warrants for $ 0.25 1,129,193 83,752 941,191 0.80 0.7490 1.40 1.2933 During the year ended March 31, 2017 a warrant holder exercised 262,045 51,249 During the year ended March 31, 2016, a warrant holder exercised 148,787 45,508 Common share purchase warrants Exercise Number of Price ($) Warrants Expiry Date 1.2933 5,873,289 February 26, 2019 1.2933 1,229,040 March 27, 2019 1.2933 328,166 March 31, 2019 1.2933 2,544,240 April 21, 2019 1.2933 1,201,164 May 27, 2019 1.2933 1,173,370 June 30, 2019 0.7490 1,313,745 February 26, 2019 13,663,014 The weighted-average remaining contractual term of the outstanding warrants was 1.52 1.77 Warrant derivative liability The Company’s outstanding common share purchase warrants include price protection provisions that allow for a reduction in the exercise price of the warrants in the event the Company subsequently issues common stock or options, rights, warrants or securities convertible or exchangeable for shares of common stock at a price lower than the exercise price of the warrants. Simultaneously with any reduction to the exercise price, the number of shares of common stock that may be purchased upon exercise of each of these warrants shall be increased based on a pre-defined formula. In addition, prior to the effectiveness of certain resale registration statements or if any such registration statements are no longer effective, the holder of the Company’s warrants, at their option, may exercise all or any part of the warrants in a “cashless” or “net-issue” exercise. The Company’s derivative instruments have been measured at fair value at inception and at each reporting period using a simulation model. The Company recognizes all of its warrants with price protection on its condensed consolidated interim Number of Warrants Value ($) Warrants issued in February 26, 2015 financing 8,509,325 550,374 Warrants issued in March 27, 2015 financing 1,333,750 1,036,325 Warrants issued in March 31, 2015 financing 980,375 759,290 Change in fair value of warrant derivative liability 6,036,659 Balance at March 31, 2015 8,382,648 Warrants issued in April 21, 2015 financing 3,426,500 2,588,722 Warrants issued in May 27, 2015 financing 1,560,625 1,025,173 Warrants issued in June 30, 2015 financing 2,238,500 1,490,969 Change in fair value of warrant derivative liability (8,290,556) Fair value of warrants exercised (60,966) Balance at March 31, 2016 5,135,990 Change in fair value of warrant derivative liability (4,176,390) Balance at March 31, 2017 959,600 Change in fair value of warrant derivative liability 4,804 Fair value of warrants exercised Note 9(a) (204,790) Balance at June 30, 2017 759,714 During the period ended June 30, 2017, the Company recorded a loss of $ 4,804 $ 391,059 condensed consolidated interim Expected Risk Number of life in Exercise free Dividend Expected Fair Grant date Warrants years Price($) Rate rate volatility value ($) At Inception: February 26, 2015 7,735,750 4 1.40 0.44 % 0 % 51.83 % 464,784 February 26, 2015 773,575 4 0.80 0.44 % 0 % 51.83 % 85,590 March 27, 2015 1,212,500 3.92 1.40 0.43 % 0 % 52.37 % 950,913 March 27, 2015 121,250 3.92 0.80 0.43 % 0 % 52.37 % 85,412 March 31, 2015 891,250 3.91 1.40 0.41 % 0 % 52.45 % 696,582 March 31, 2015 89,125 3.91 0.80 0.41 % 0 % 52.45 % 62,708 April 21, 2015 3,115,000 3.85 1.40 0.68 % 0 % 51.54 % 2,371,956 April 21, 2015 311,500 3.85 0.80 0.68 % 0 % 51.54 % 216,766 May 27, 2015 1,418,750 3.76 1.40 0.46 % 0 % 51.74 % 933,065 May 27, 2015 141,875 3.76 0.80 0.46 % 0 % 51.74 % 92,108 June 30, 2015 2,035,000 3.66 1.40 0.37 % 0 % 52.94 % 1,356,512 June 30, 2015 203,500 3.66 0.80 0.37 % 0 % 52.94 % 134,457 At Year End: March 31, 2017 16,408,250 1.91 1.40 0.65 % 0 % 53.58 % 849,713 March 31, 2017 1,229,993 1.91 0.80 0.65 % 0 % 53.58 % 109,887 At Period End June 30, 2017 12,349,269 1.91 1.2933 0.65 % 0 % 53.58 % 667,184 June 30, 2017 1,313,745 1.91 0.7490 0.65 % 0 % 53.58 % 92,530 In addition to the forgoing, the Company also utilized a holding cost to approximate the impact of a holder of the warrant to maintain a hedging strategy in which they maintained a short position. On analysis of comparable companies and other information the Company has determined that the use of 2.25 The warrant derivative liability is classified within Level 3 of the fair value hierarchy because on initial recognition and again at each reporting period, it was valued using these significant inputs and assumptions that are unobservable in the market. Changes in the values assumed and used in the simulation model can materially affect the estimate of fair value. Generally, an increase in the market price of the Company’s shares of common stock, an increase in the volatility of the Company’s shares of common stock and an increase in the expected life would result in a directionally similar change in the estimated fair value of the warrant derivative liability. An increase in the risk free rate would result in a decrease in the fair value of the warrant derivative liability. The expected life is based on the remaining contractual term of the warrants. The risk free rate was based on U.S. treasury-note yields with terms commensurate with the remaining term of the warrants. Expected volatility over the expected term of the warrants is estimated based on consideration of historical volatility and other information. In addition to the assumptions above, the Company also took into consideration the probability of the Company’s participation in another round of financing, the type of such financing and the range of the stock price for the financing at that time. At each increment of the simulation, the daily volume weighted-average price was calculated. If this amount was 200

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	3 Months Ended
	Jun. 30, 2017
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies Disclosure [Text Block]	12. COMMITMENTS AND CONTINGENCIES Contingencies From time to time, the Company may be involved in a variety of claims, suits, investigations and proceedings arising in the ordinary course of our business, collections claims, breach of contract claims, labor and employment claims, tax and other matters. Although claims, suits, investigations and proceedings are inherently uncertain and their results cannot be predicted with certainty, the Company believes that the resolution of current pending matters will not have a material adverse effect on its business, financial position, results of operations or cash flow. Regardless of the outcome, litigation can have an adverse impact on the Company because of legal costs, diversion of management resources and other factors. Commitments On February 25, 2015, 262,904 241,185 210,323 314,560 320,000

RISK MANAGEMENT

RISK MANAGEMENT	3 Months Ended
	Jun. 30, 2017
Risks and Uncertainties [Abstract]
Concentration Risk Disclosure [Text Block]	13. RISK MANAGEMENT The Company’s cash balances are maintained in two banks in Canada and a Canadian Bank subsidiary in the US. US Bank Deposits held in banks in Canada are insured up to $ 100,000 Interest Rate Risk Interest rate risk is the risk that the value of a financial instrument might be adversely affected by a change in the interest rates. The Company has minimal exposure to fluctuations in the market interest rate. In seeking to minimize the risks from interest rate fluctuations the Company manages exposure through its normal operating and financing activities. Liquidity Risk Liquidity risk is the risk that the Company will incur difficulties meeting its financial obligations, as they are due. The Company’s approach to managing liquidity is to ensure, as far as possible, that it will have sufficient liquidity to meet its liabilities when due. Accounts payable and accrued liabilities are due within the current operating period. The Company has funded its operations through the issuance of capital stock, convertible debt and loans in addition to grants and investment tax credits received from the Government of Canada.

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS	3 Months Ended
	Jun. 30, 2017
Subsequent Events [Abstract]
Subsequent Events [Text Block]	14. SUBSEQUENT EVENTS a) Subsequent to June 30, 2017, the Company granted at market price 250,000 1,500,000 500,000

SIGNIFICANT ACCOUNTING POLICI22

SIGNIFICANT ACCOUNTING POLICIES (Policies)	3 Months Ended
	Jun. 30, 2017
Accounting Policies [Abstract]
Unaudited Condensed Consolidated Interim Financial Statements [Policy Text Block]	These unaudited condensed consolidated interim financial statements have been prepared on the same basis as the annual audited financial statements of the Company and should be read in conjunction with those annual audited financial statements filed on Form 10-K for the year ended March 31, 2017. In the opinion of management, these unaudited condensed consolidated interim financial statements reflect adjustments, necessary to present fairly the Company’s financial position, results of operations and cash flows for the periods shown. The results of operations for such periods are not necessarily indicative of the results expected for a full year or for any future period.
Recently Adopted Accounting Pronouncements [Policy Text Block]	Newly Adopted and Recently Issued Accounting Pronouncements In May 2014, the FASB issued ASU No. 2014-09, “Revenue from Contracts with Customers (Topic 606)”. The standard outlines a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and supersedes most current revenue recognition guidance. The accounting standard is effective for annual reporting periods (including interim reporting periods within those periods) beginning after December 15, 2017. Early adoption is not permitted. The impact on the condensed consolidated interim In August 2014, the FASB issued a new financial accounting standard on going concern, ASU No. 2014-15, “Presentation of Financial Statements – Going Concern (Sub-Topic 205-40): Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern.” The standard provides guidance about management’s responsibility to evaluate whether there is a substantial doubt about the organization’s ability to continue as a going concern. The amendments in this Update apply to all companies. They become effective in the annual period ending after December 15, 2016, with early application permitted. The Company has adopted this ASU No. 2014-15 as at and for the year ended March 31, 2017. There was no material effect on the condensed consolidated interim In November 2015, the FASB issued ASU No. 2015-17, “Balance Sheet Classification of Deferred Taxes,” which requires that deferred tax liabilities and assets be classified on our Consolidated Balance Sheets as noncurrent based on an analysis of each taxpaying component within a jurisdiction. ASU No. 2015-17 is effective for the fiscal year commencing after December 15, 2017. The Company does not anticipate that the adoption of ASU No. 2015-17 will have a material effect on the condensed consolidated interim In January 2016, the FASB issued ASU No. 2016-01 Financial Instruments - Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities. The updates makes several modifications to Subtopic 825-10, including the elimination of the available-for-sale classification of equity investments, and it requires equity investments with readily determinable fair values to be measured at fair value with changes in fair value recognized in operations. The update is effective for fiscal years beginning after December 2017. The Company is still assessing the impact that the adoption of ASU 2016-01 will have on the condensed consolidated interim In February 2016, the FASB issued ASU 2016-02, Leases. This update requires organizations that lease assets to recognize on the balance sheet the assets and liabilities for the rights and obligations created by those leases. The new guidance will also require additional disclosure about the amount, timing and uncertainty of cash flows arising from leases. The provisions of this update are effective for annual and interim periods beginning after December 15, 2018. The Company is still assessing the impact that the adoption of ASU 2016-02 will have on the condensed consolidated interim In March 2016, the FASB issued ASU 2016-09, “Compensation - Stock Compensation: Improvements to Employee Share-Based Payment Accounting”. Several aspects of the accounting for share-based payment award transaction are simplified, including (a) income tax consequences; (b) classification of awards as either equity or liabilities; and (c) classification on the statement of cash flows. The amendments are effective for annual periods beginning after December 15, 2016, and interim periods within those annual periods. The Company has adopted this policy during the period and there was no impact on the condensed consolidated interim financial statements. In August 2016, the FASB issued ASU 2016-15, “Statement of Cash Flows: Classification of Certain Cash Receipts and Cash Payments”. This ASU provides eight targeted changes to how cash receipts and cash payments are presented and classified in the statement of cash flows. ASU 2016-15 is effective for the fiscal year commencing after December 15, 2017. The Company is still assessing the impact that the adoption of ASU 2016-15 will have on the condensed consolidated interim In January 2017, the FASB issued ASU 2017-01, “Business Combinations: Clarifying the definition of a Business” which amends the current definition of a business. Under ASU 2017-01, to be considered a business, an acquisition would have to include an input and a substantive process that together significantly contributes to the ability to create outputs. ASU 2017-01 further states that when substantially all of the fair value of gross assets acquitted is concentrated in a single asset (or a group of similar assets), the assets acquired would not represent a business. The new guidance also narrows the definition of the term “outputs” to be consistent with how it described in Topic 606, Revenue from Contracts with Customers. The changes to the definition of a business will likely result in more acquisitions being accounted for as asset acquisitions. ASU 2017-01 is effective for acquisitions commencing on or after June 30, 2019, with early adoption permitted. Adoption of this guidance will be applied prospectively on or after the effective date. In January 2017, the FASB issued ASU 2017-04, “Intangibles – Goodwill and Other” ASU 2017-04 simplifies the accounting for goodwill impairment by eliminating Step 2 of the current goodwill impairment test, which required a hypothetical purchase price allocation. Goodwill impairment will now be the amount by which the reporting unit’s carrying value exceeds its fair value, limited to the carrying value of the goodwill. ASU 2017-04 is effective for financial statements issued for fiscal years, and interim periods beginning after December 15, 2019.
Revenue Recognition, Policy [Policy Text Block]	Revenue Recognition The Company recognizes revenue from product sales when persuasive evidence of an agreement with customer exists, products are shipped or title passes pursuant to the terms of the agreement, the amount due from the customer is fixed or determinable, collectability is reasonably assured, and there are no significant future performance obligation. Deposits are carried as liabilities until the requirements for revenue recognition are met.
Warrant Derivative Liability Policy [Policy Text Block]	Significant Judgments - Warrant Derivative Liability The Company’s derivative warrant instruments are measured at fair value using a simulation model which takes into account, as of the valuation date, factors including the current exercise price, the expected life of the warrant, the current price of the underlying stock, its expected volatility, holding cost and the risk-free interest rate for the term of the warrant (Note 11). The warrant derivative liability is revalued at each reporting period and changes in fair value are recognized in the condensed consolidated interim statements of operations and comprehensive loss under the caption “Change in fair value of warrant derivative liability”. The selection of the appropriate valuation model and the inputs and assumptions that are required to determine the valuation requires significant judgment and requires management to make estimates and assumptions that affect the reported amount of the related liability and reported amounts of the change in fair value. Actual results could differ from those estimates, and changes in these estimates are recorded when known. As the derivative warrant liability is required to be measured at fair value at each reporting date it is reasonably possible that these estimates and assumptions could change in the near term.
Standard Product Warranty, Policy [Policy Text Block]	Warranty Reserve and Deferred Warranty Revenue The Company provides a one-year warranty as part of its normal sales offering. When products are sold, the Company provides warranty reserves, which, based on the historical experience of the Company are sufficient to cover warranty claims. Accrued warranty reserves are included in accrued liabilities on the balance sheet amounted to $ 64,957 15,190
Foreign Currency Transactions and Translations Policy [Policy Text Block]	Foreign Currency Translation The functional currency of the Company and its wholly owned subsidiaries is the U.S. dollar. Transactions denominated in a currency other than the functional currency are recorded on initial recognition at the exchange rate at the date of the transaction. After initial recognition, monetary assets and liabilities denominated in foreign currency are translated at the end of each reporting period into the functional currency at the exchange rate at that date. Exchange differences are recognized in profit or loss. Non-monetary assets and liabilities measured at cost are translated at the exchange rate at the date of the transaction.
Fair Value of Financial Instruments, Policy [Policy Text Block]	Fair Value of Financial Instruments ASC Topic 820 defines fair value, establishes a framework for measuring fair value, and expands disclosures about fair value measurements. Included in the ASC Topic 820 framework is a three level valuation inputs hierarchy with Level 1 being inputs and transactions that can be effectively fully observed by market participants spanning to Level 3 where estimates are unobservable by market participants outside of the Company and must be estimated using assumptions developed by the Company. The Company discloses the lowest level input significant to each category of asset or liability valued within the scope of ASC Topic 820 and the valuation method as exchange, income or use. The Company uses inputs which are as observable as possible and the methods most applicable to the specific situation of each company or valued item. The carrying amounts reported in the balance sheets for cash and cash equivalents, accounts receivable, other receivables, accounts payable and accrued liabilities, due from related parties approximate fair value because of the short period of time between the origination of such instruments and their expected realization and their current market rates of interest. Per ASC Topic 820 framework these are considered Level 2 inputs where inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices in active markets for similar assets or liabilities, quoted prices for identical or similar assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. As at June 30, 2017 and March 31, 2017, the Company’s warrant derivative liability was measured at fair value at each reporting period using a simulation model based on Level 3 inputs. The Company’s policy is to recognize transfers into and out of Level 3 as of the date of the event or change in the circumstances that caused the transfer. There were no such transfers during the period.

ACQUISITION (Tables)

ACQUISITION (Tables)	3 Months Ended
	Jun. 30, 2017
Business Combinations [Abstract]
Schedule of Business Acquisitions, by Acquisition [Table Text Block]	As at April 21, 2016 $ Fair value of 23,650,000 shares of common stock (a) 23,177,000 Fair value of vested stock options (b) 2,582,890 Allocation of purchase price: 25,759,890 Cash and cash equivalents 266,635 Accounts receivable 6,490 Inventories 188,879 Prepaid expenses and other current assets 16,839 Equipment 59,749 Liabilities assumed: Accounts payable (241,299) Accrued liabilities (361,029) Customer deposits (86,487) Demand notes payable (324,894) Promissory notes payable (217,808) Bionik advance (c) (1,436,164) Net assets acquired (2,129,089) Patents and exclusive License Agreement 1,306,031 Trademark 2,505,907 Customer relationships 1,431,680 Non compete agreement 61,366 Assembled Workforce 275,720 Goodwill 22,308,275 25,759,890 (a) The fair value of common stock was based on $ 0.98 (b) The fair value of the vested stock options was determined using the Black Scholes option pricing model with the following key assumptions: a risk free rate of 1.59 0 114 (c) Included in the net assets acquired was a loan issued to IMT in the amount of $ 300,000 6 200,000
Business Acquisition, Pro Forma Information [Table Text Block]	The schedule below reflects the intangible assets acquired in the IMT acquisition and the assets amortization period and expense for the three month period ended June 30, 2017 and the year ended March 31, 2017: Intangible Amortization Expense March Value at March Expense June Value at June assets acquired period (years) Value acquired 31, 2017 31, 2017 30, 2017 30, 2017 $ $ $ $ $ Patents and exclusive License Agreement 9.74 1,306,031 126,375 1,179,656 33,559 1,146,097 Trademark Indefinite 2,505,907 - 2,505,907 - 2,505,907 Customer relationships 10 1,431,680 134,931 1,296,749 35,830 1,260,919 Non compete agreement 2 61,366 28,918 32,448 7,696 24,752 Assembled Workforce 1 275,720 259,856 15,864 15,864 - 5,580,704 550,080 5,030,624 92,949 4,937,675

PREPAID EXPENSES AND OTHER RE24

PREPAID EXPENSES AND OTHER RECEIVABLES (Tables)	3 Months Ended
	Jun. 30, 2017
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]	June 30, March 31, 2017 2017 $ $ Prepaid expenses and sundry receivables 76,828 68,484 Prepaid insurance 81,166 136,896 Sales taxes receivable (i) 14,057 22,667 172,051 228,047 (i) Sales tax receivable represents net harmonized sales taxes (HST) input tax credits receivable from the Government of Canada.

INVENTORIES (Tables)

INVENTORIES (Tables)	3 Months Ended
	Jun. 30, 2017
Inventory Disclosure [Abstract]
Schedule of Inventory, Current [Table Text Block]	June 30, March 31, 2017 2017 $ $ Raw materials 137,783 119,985 Work in progress 59,163 108,264 Finished Goods 58,600 - 255,546 228,249

EQUIPMENT (Tables)

EQUIPMENT (Tables)	3 Months Ended
	Jun. 30, 2017
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment [Table Text Block]	June 30, 2017 March 31, 2017 Accumulated Accumulated Cost Depreciation Net Cost Depreciation Net $ $ $ $ $ $ Computers and electronics 250,538 209,805 40,733 250,538 204,258 46,280 Furniture and fixtures 36,795 26,623 10,172 36,795 26,096 10,699 Demonstration equipment 200,186 61,221 138,965 184,586 44,420 140,166 Manufacturing equipment 88,742 85,166 3,576 88,742 84,982 3,760 Tools and parts 11,422 4,813 6,609 11,422 4,472 6,950 Assets under capital lease 23,019 4,605 18,414 23,019 3,453 19,566 610,702 392,233 218,469 595,102 367,681 227,421

NOTES PAYABLE (Tables)

NOTES PAYABLE (Tables)	3 Months Ended
	Jun. 30, 2017
Demand Notes payable [Member]
Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]	Balance, March 31, 2017 330,600 Accrued interest 2,341 Balance, June 30, 2017 $ 332,941
Promissory Note [Member]
Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]	Balance, March 31, 2017 236,548 Accrued interest 5,152 Balance, June 30, 2017 $ 241,700

SHARE CAPITAL (Tables)

SHARE CAPITAL (Tables)	3 Months Ended
	Jun. 30, 2017
Stockholders' Equity Note [Abstract]
Schedule of Stockholders Equity [Table Text Block]	June 30, 2017 March 31, 2017 Number of Number of shares $ shares $ Exchangeable Shares: Balance beginning of period/year 47,909,336 47,910 50,000,000 50,000 Converted into common shares - - (2,090,664) (2,090) Balance at the end of period/year 47,909,336 47,910 47,909,336 47,910 Common Shares Balance at beginning of the period 48,885,107 48,884 22,591,292 22,591 Shares issued on acquisition (Note 3) - - 23,650,000 23,650 Shares issued to exchangeable shares - - 2,090,664 2,090 Shares issued for services - - 217,047 217 Options exercised - - 110,096 110 Warrants exercise (a) 5,000,172 5,000 174,759 175 Cashless exercise of warrants - - 51,249 51 Balance at end of the period 53,885,279 53,884 48,885,107 48,884 TOTAL COMMON SHARES 101,794,615 101,794 96,794,443 96,794 (a) During the three month period ended June 30, 2017, the Company consummated an offer to amend and exercise to its warrant holders, enabling them to exercise their outstanding warrants for $ 0.25 5,000,172 1,125,038 (b) During the three month period ended June 30, 2016, 51,249 262,045 0.80 43,562 (c) The Company issued 70,000 59,500

STOCK OPTIONS (Tables)

STOCK OPTIONS (Tables)	3 Months Ended
	Jun. 30, 2017
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Share-based Compensation, Performance Shares Award Outstanding Activity [Table Text Block]	Exercise Price ($) Number of Options Expiry Date Exercisable Options 0.165 264,230 April 1, 2021 264,230 0.23 97,514 June 20, 2021 97,514 0.23 1,981,728 July 1, 2021 1,981,728 0.23 204,471 February 17, 2022 204,471 1.22 400,000 November 24, 2022 133,333 1.00 2,316,667 December 14, 2022 809,994 0.95 111,937 March 28, 2023 111,937 1.05 433,027 March 28, 2023 433,027 1.00 250,000 April 26, 2023 - 1.00 750,000 August 8, 2023 - 0.70 400,000 February 6, 2024 - 0.68 250,000 February 13, 2024 - 0.95 31,620 March 3, 2024 31,620 1.05 122,324 March 3, 2024 122,324 0.95 15,810 March 14, 2024 15,810 1.05 61,162 March 14, 2024 61,162 0.95 82,213 September 30, 2024 82,213 1.05 318,042 September 30, 2024 318,042 0.95 7,431 June 2, 2025 7,431 1.05 28,747 June 2, 2025 28,747 0.25 906,077 July 28, 2025 906,077 0.95 671,859 July 29, 2025 671,859 0.25 66,298 December 30, 2025 53,909 0.95 49,160 December 30, 2025 27,261 9,820,317 6,362,689

WARRANTS (Tables)

WARRANTS (Tables)	3 Months Ended
	Jun. 30, 2017
Warrants and Rights Note Disclosure [Abstract]
Schedule Of Share Based Compensation Stock Purchase Warrants Activity [Table Text Block]	The following is a continuity schedule of the Company’s common share purchase warrants: Weighted-Average Number of Warrants Exercise Price ($) Outstanding and exercisable, March 31, 2015 10,823,450 1.35 Issued 7,225,625 1.35 Exercised (148,787) (0.80) Outstanding and exercisable, March 31, 2016 17,900,288 1.35 Exercised (262,045) (0.80) Outstanding and exercisable, March 31, 2017 17,638,243 1.35 Exercised (5,000,172) 0.25 Dilution warrants issued to $0.80 warrant holders 83,752 0.749 Dilution warrants issued to $1.40 warrant holders 941,191 1.2933 Outstanding at June 30, 2017 13,663,014 1.241
Schedule of Common Share Purchase Warrants Outstanding [Table Text Block]	Exercise Number of Price ($) Warrants Expiry Date 1.2933 5,873,289 February 26, 2019 1.2933 1,229,040 March 27, 2019 1.2933 328,166 March 31, 2019 1.2933 2,544,240 April 21, 2019 1.2933 1,201,164 May 27, 2019 1.2933 1,173,370 June 30, 2019 0.7490 1,313,745 February 26, 2019 13,663,014
Schedule Of Warrant derivative liability [Table Text Block]	The following summarizes the changes in the value of the warrant derivative liability from inception until June 30, 2017: Number of Warrants Value ($) Warrants issued in February 26, 2015 financing 8,509,325 550,374 Warrants issued in March 27, 2015 financing 1,333,750 1,036,325 Warrants issued in March 31, 2015 financing 980,375 759,290 Change in fair value of warrant derivative liability 6,036,659 Balance at March 31, 2015 8,382,648 Warrants issued in April 21, 2015 financing 3,426,500 2,588,722 Warrants issued in May 27, 2015 financing 1,560,625 1,025,173 Warrants issued in June 30, 2015 financing 2,238,500 1,490,969 Change in fair value of warrant derivative liability (8,290,556) Fair value of warrants exercised (60,966) Balance at March 31, 2016 5,135,990 Change in fair value of warrant derivative liability (4,176,390) Balance at March 31, 2017 959,600 Change in fair value of warrant derivative liability 4,804 Fair value of warrants exercised Note 9(a) (204,790) Balance at June 30, 2017 759,714
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]	Expected Risk Number of life in Exercise free Dividend Expected Fair Grant date Warrants years Price($) Rate rate volatility value ($) At Inception: February 26, 2015 7,735,750 4 1.40 0.44 % 0 % 51.83 % 464,784 February 26, 2015 773,575 4 0.80 0.44 % 0 % 51.83 % 85,590 March 27, 2015 1,212,500 3.92 1.40 0.43 % 0 % 52.37 % 950,913 March 27, 2015 121,250 3.92 0.80 0.43 % 0 % 52.37 % 85,412 March 31, 2015 891,250 3.91 1.40 0.41 % 0 % 52.45 % 696,582 March 31, 2015 89,125 3.91 0.80 0.41 % 0 % 52.45 % 62,708 April 21, 2015 3,115,000 3.85 1.40 0.68 % 0 % 51.54 % 2,371,956 April 21, 2015 311,500 3.85 0.80 0.68 % 0 % 51.54 % 216,766 May 27, 2015 1,418,750 3.76 1.40 0.46 % 0 % 51.74 % 933,065 May 27, 2015 141,875 3.76 0.80 0.46 % 0 % 51.74 % 92,108 June 30, 2015 2,035,000 3.66 1.40 0.37 % 0 % 52.94 % 1,356,512 June 30, 2015 203,500 3.66 0.80 0.37 % 0 % 52.94 % 134,457 At Year End: March 31, 2017 16,408,250 1.91 1.40 0.65 % 0 % 53.58 % 849,713 March 31, 2017 1,229,993 1.91 0.80 0.65 % 0 % 53.58 % 109,887 At Period End June 30, 2017 12,349,269 1.91 1.2933 0.65 % 0 % 53.58 % 667,184 June 30, 2017 1,313,745 1.91 0.7490 0.65 % 0 % 53.58 % 92,530

NATURE OF OPERATIONS (Details T

NATURE OF OPERATIONS (Details Textual) - USD ($)	1 Months Ended		3 Months Ended
	Apr. 21, 2016	Feb. 26, 2015	Jun. 30, 2017	Jun. 30, 2016	Mar. 31, 2017	Dec. 31, 2014
Working Capital Surplus (Deficit)			$ 4,937,770		$ 4,375,225
Comprehensive Income (Loss), Net of Tax, Attributable to Parent			$ (2,245,322)	$ (2,322,772)
Stockholders' Equity, Reverse Stock Split			1-for-0.831105
Common Stock, Shares Authorized			150,000,000		150,000,000	200,000,000
Retained Earnings (Accumulated Deficit)			$ (17,833,876)		$ (15,588,554)
Interactive Motion Technologies, Inc. [Member]
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares	23,650,000
Share Exchange Agreement [Member]
Stock Issued During Period, Shares, New Issues		50,000,000
Debt Instrument, Convertible, Conversion Ratio		3.14
Variable Interest Entity, Qualitative or Quantitative Information, Ownership Percentage		100.00%

SIGNIFICANT ACCOUNTING POLICI32

SIGNIFICANT ACCOUNTING POLICIES (Details Textual) - USD ($)	3 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Mar. 31, 2017
Significant Accounting Policies [Line Items]
Standard and Extended Product Warranty Accrual	$ 64,957		$ 64,957
Product Warranty Expense		$ 15,190

ACQUISITION (Details)

ACQUISITION (Details) - USD ($)		1 Months Ended
		Apr. 21, 2016	Jun. 30, 2017	Mar. 31, 2017
Business Acquisition [Line Items]
Fair value of 23,650,000 shares of common stock	[1]	$ 23,177,000
Fair value of vested stock options	[2]	2,582,890
Total Consideration Paid		25,759,890
Allocation of purchase price:
Cash and cash equivalents		266,635
Accounts receivable		6,490
Inventories		188,879
Prepaid expenses and other current assets		16,839
Equipment		59,749
Liabilities assumed:
Accounts payable		(241,299)
Accrued liabilities		(361,029)
Customer deposits		(86,487)
Demand notes payable		(324,894)
Promissory notes payable		(217,808)
Bionik advance	[3]	(1,436,164)
Net assets acquired		(2,129,089)
Goodwill		22,308,275	$ 22,308,275	$ 22,308,275
Total Allocation of purchase price		25,759,890
Patents and exclusive License Agreement [Member]
Liabilities assumed:
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill		1,306,031
Customer Relationships [Member]
Liabilities assumed:
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill		1,431,680
Non compete agreement [Member]
Liabilities assumed:
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill		61,366
Assembled Workforce [Member]
Liabilities assumed:
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill		275,720
Trademarks [Member]
Liabilities assumed:
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill		$ 2,505,907
[1]	The fair value of common stock was based on $0.98, which was the closing market price of the Company’s common stock on April 21, 2016.
[2]	The fair value of the vested stock options was determined using the Black Scholes option pricing model with the following key assumptions: a risk free rate of 1.59%, dividend and forfeiture rates of 0% and expected volatility of 114% which is consistent with the Company’s assumptions (Note 10).
[3]	The schedule below reflects the intangible assets acquired in the IMT acquisition and the assets amortization period and expense for the three month period ended June 30, 2017 and the year ended March 31, 2017:

ACQUISITION (Details 1)

ACQUISITION (Details 1) - USD ($)	1 Months Ended	3 Months Ended		12 Months Ended
	Apr. 21, 2016	Jun. 30, 2017	Jun. 30, 2016	Mar. 31, 2017
Business Acquisition [Line Items]
Noncash or Part Noncash Acquisition, Intangible Assets Acquired	$ 5,580,704	$ 5,580,704
Amortization of Intangible Assets		92,949	$ 0	$ 550,080
Intangible Assets, Net (Excluding Goodwill)		4,937,675		$ 5,030,624
Patents and exclusive License Agreement [Member]
Business Acquisition [Line Items]
Finite-Lived Intangible Asset, Useful Life				9 years 8 months 26 days
Noncash or Part Noncash Acquisition, Intangible Assets Acquired		1,306,031
Amortization of Intangible Assets		33,559		$ 126,375
Intangible Assets, Net (Excluding Goodwill)		1,146,097		$ 1,179,656
Trademark [Member]
Business Acquisition [Line Items]
Finite-Lived Intangible Asset, Useful Life				Indefinite
Noncash or Part Noncash Acquisition, Intangible Assets Acquired		2,505,907
Amortization of Intangible Assets		0		$ 0
Intangible Assets, Net (Excluding Goodwill)		2,505,907		$ 2,505,907
Customer relationships [Member]
Business Acquisition [Line Items]
Finite-Lived Intangible Asset, Useful Life				10 years
Noncash or Part Noncash Acquisition, Intangible Assets Acquired		1,431,680
Amortization of Intangible Assets		35,830		$ 134,931
Intangible Assets, Net (Excluding Goodwill)		1,260,919		$ 1,296,749
Non compete agreement [Member]
Business Acquisition [Line Items]
Finite-Lived Intangible Asset, Useful Life				2 years
Noncash or Part Noncash Acquisition, Intangible Assets Acquired		61,366
Amortization of Intangible Assets		7,696		$ 28,918
Intangible Assets, Net (Excluding Goodwill)		24,752		$ 32,448
Assembled Workforce [Member]
Business Acquisition [Line Items]
Finite-Lived Intangible Asset, Useful Life				1 year
Noncash or Part Noncash Acquisition, Intangible Assets Acquired		275,720
Amortization of Intangible Assets		15,864		$ 259,856
Intangible Assets, Net (Excluding Goodwill)		$ 0		$ 15,864

ACQUISITION (Details Textual)

ACQUISITION (Details Textual)	1 Months Ended
	Apr. 21, 2016USD ($)$ / sharesshares
Business Acquisition [Line Items]
Fair Value Assumptions, Risk Free Interest Rate	1.59%
Fair Value Assumption Forfeited rate	0.00%
Fair Value Assumptions, Expected Volatility Rate	114.00%
Exercise Price 0.25 [Member]
Business Acquisition [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number	1,000,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price | $ / shares	$ 0.25
Exercise Price 0.95 [Member]
Business Acquisition [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number	1,000,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price | $ / shares	$ 0.95
Exercise Price 1.05 [Member]
Business Acquisition [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number	1,000,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price | $ / shares	$ 1.05
Interactive Motion Technologies, Inc. [Member]
Business Acquisition [Line Items]
Business Acquisition, Percentage of Voting Interests Acquired	100.00%
Business Acquisition, Effective Date of Acquisition	Apr. 21, 2016
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares	23,650,000
Business Acquisition, Number Of Option Acquired	3,895,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number	3,000,000
Allocated Share-based Compensation Expense | $	$ 2,582,890
Share Price | $ / shares	$ 0.98
Stock Issued During Period, Shares, Acquisitions	300,000
Debt Instrument, Interest Rate, Stated Percentage	6.00%
Subordinated Debt | $	$ 200,000

PREPAID EXPENSES AND OTHER RE36

PREPAID EXPENSES AND OTHER RECEIVABLES (Details) - USD ($)		Jun. 30, 2017	Mar. 31, 2017
Prepaid Expense And Other Receivables [Line Items]
Prepaid expenses and sundry receivables		$ 76,828	$ 68,484
Prepaid insurance		81,166	136,896
Sales taxes receivable	[1]	14,057	22,667
Prepaid Expense and Other Assets		$ 172,051	$ 228,047
[1]	Sales tax receivable represents net harmonized sales taxes (HST) input tax credits receivable from the Government of Canada.

INVENTORIES (Details)

INVENTORIES (Details) - USD ($)	Jun. 30, 2017	Mar. 31, 2017
Inventory [Line Items]
Raw Materials	$ 137,783	$ 119,985
Work in Progress	59,163	108,264
Finished Goods	58,600	0
Inventory, Net	$ 255,546	$ 228,249

EQUIPMENT (Details)

EQUIPMENT (Details) - USD ($)	Jun. 30, 2017	Mar. 31, 2017
Property, Plant and Equipment [Line Items]
Equipment, Cost	$ 610,702	$ 595,102
Accumulated Depreciation	392,233	367,681
Equipment, Net	218,469	227,421
Computers and electronics [Member]
Property, Plant and Equipment [Line Items]
Equipment, Cost	250,538	250,538
Accumulated Depreciation	209,805	204,258
Equipment, Net	40,733	46,280
Furniture and fixtures [Member]
Property, Plant and Equipment [Line Items]
Equipment, Cost	36,795	36,795
Accumulated Depreciation	26,623	26,096
Equipment, Net	10,172	10,699
Demonstration equipment [Member]
Property, Plant and Equipment [Line Items]
Equipment, Cost	200,186	184,586
Accumulated Depreciation	61,221	44,420
Equipment, Net	138,965	140,166
Manufacturing equipment [Member]
Property, Plant and Equipment [Line Items]
Equipment, Cost	88,742	88,742
Accumulated Depreciation	85,166	84,982
Equipment, Net	3,576	3,760
Tools and parts [Member]
Property, Plant and Equipment [Line Items]
Equipment, Cost	11,422	11,422
Accumulated Depreciation	4,813	4,472
Equipment, Net	6,609	6,950
Assets under capital lease [Member]
Property, Plant and Equipment [Line Items]
Equipment, Cost	23,019	23,019
Accumulated Depreciation	4,605	3,453
Equipment, Net	$ 18,414	$ 19,566

EQUIPMENT (Details Textual)

EQUIPMENT (Details Textual) - USD ($)	3 Months Ended
	Jun. 30, 2017	Jun. 30, 2016
Property, Plant and Equipment [Line Items]
Depreciation	$ 24,552	$ 10,163

NOTES PAYABLE (Details)

NOTES PAYABLE (Details) - IMT Notes [Member] - USD ($)	3 Months Ended
	Jun. 30, 2017	Jun. 30, 2016
Balance, March 31, 2017	$ 330,600
Accrued interest	2,341	$ 3,325
Balance, June 30, 2017	$ 332,941

NOTES PAYABLE (Details 1)

NOTES PAYABLE (Details 1) - USD ($)	3 Months Ended
	Jun. 30, 2017	Jun. 30, 2016
Balance, March 31, 2017	$ 236,548
Balance, June 30, 2017	241,700
Promissory Note [Member]
Balance, March 31, 2017	236,548
Accrued interest	5,152	$ 3,890
Balance, June 30, 2017	$ 241,700

NOTES PAYABLE (Details Textual)

NOTES PAYABLE (Details Textual) - USD ($)	Jul. 05, 2017	Jun. 30, 2017	Jun. 30, 2016	Mar. 31, 2017	Jan. 15, 2017	Dec. 31, 2016	Apr. 21, 2016	Feb. 28, 2014
Convertible Debt [Member]
Debt Instrument [Line Items]
Debt Instrument, Interest Rate, Stated Percentage		12.00%
Debt Instrument, Face Amount				$ 2,000,000		$ 1,500,000
Debt Instrument, Maturity Date		Nov. 15, 2017
Debt Instrument, Convertible, Terms of Conversion Feature		The convertible loans contain the following terms: convertible at the option of the holder at the price of the equity financing or payable on demand upon the completion of an equity financing greater than $5,000,000; automatically convertible at the price of the equity financing upon completion of an equity financing between $3,500,000 and $5,000,000
Convertible Loans Payable [Member]
Debt Instrument [Line Items]
Debt Instrument, Interest Rate, Stated Percentage		10.00%
Interest Payable, Current		$ 60,493		17,488
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right		300,000
First Tranches [Member] | Convertible Debt [Member]
Debt Instrument [Line Items]
Debt Instrument, Face Amount						$ 500,000
Second Tranches [Member] | Convertible Debt [Member]
Debt Instrument [Line Items]
Debt Instrument, Face Amount					$ 500,000
Third Tranches [Member] | Convertible Debt [Member]
Debt Instrument [Line Items]
Debt Instrument, Face Amount				500,000
IMT Notes [Member]
Debt Instrument [Line Items]
Debt Instrument Demand Deferral, Minimum Capital Proceeds Required		$ 15,000,000
Notes Payable		$ 332,941		330,600			$ 330,600
Debt Instrument, Interest Rate, Stated Percentage		3.50%
Interest Expense, Debt		$ 2,341	$ 3,325
Promissory Note [Member]
Debt Instrument [Line Items]
Notes Payable								$ 200,000
Debt Instrument, Interest Rate, Stated Percentage								10.00%
Interest Expense, Debt		5,152	$ 3,890
Promissory Note [Member] | Subsequent Event [Member]
Debt Instrument [Line Items]
Interest Expense, Debt	$ 41,700
Director [Member] | IMT Notes [Member]
Debt Instrument [Line Items]
Notes Payable		151,737		$ 150,689
Joint Venture Partner [Member] | Convertible Debt [Member]
Debt Instrument [Line Items]
Interest Expense, Debt		$ 3,529
Debt Instrument, Convertible, Terms of Conversion Feature		the Companys Chinesejoint venture partners loaned the Company $500,000 with an interest rate of 8% convertible into the Companys common shares upon a capital raise (Qualified Financing) where gross proceeds exceed $3,000,000 at the lesser of $0.50 and the quotient of the outstanding balance on conversion date by the price of the Qualified Financing. Additionally, the holders are entitled to warrants equaling 25% of the number of conversion sharesto be issued at conversion.

RELATED PARTY TRANSACTIONS AN43

RELATED PARTY TRANSACTIONS AND BALANCES (Details Textual) - USD ($)	3 Months Ended	12 Months Ended
	Jun. 30, 2017	Mar. 31, 2017	Jun. 30, 2016	Jun. 08, 2009
Related Party Transaction [Line Items]
Accrued interest receivable	$ 635	$ 707
Royalty on Sales, Percentage				1.00%
Related Party Transaction, Rate	1.00%
Accounts Payable, Current	$ 890,624	784,726
Repayments of Notes Payable	33,000
IMT Notes [Member]
Related Party Transaction [Line Items]
Debt Instrument Demand Deferral, Minimum Capital Proceeds Required	15,000,000
Director [Member]
Related Party Transaction [Line Items]
Accounts Payable, Current	120,000		$ 120,000
Chief Executive Officer [Member]
Related Party Transaction [Line Items]
Accounts Payable, Related Parties	8,882		1,118
Chief Technology Officer [Member]
Related Party Transaction [Line Items]
Due from Related Parties	19,366	$ 18,731
Accounts Payable, Related Parties	23,565		$ 16,941
Chief Financial Officer [Member]
Related Party Transaction [Line Items]
Accounts Payable, Related Parties	1,946
Chief Commercial Officer [Member]
Related Party Transaction [Line Items]
Accounts Payable, Related Parties	$ 0
Interactive Motion Technologies, Inc. [Member] | Director [Member]
Related Party Transaction [Line Items]
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares	5,190,376
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period	360,231

SHARE CAPITAL (Details)

SHARE CAPITAL (Details) - USD ($)		3 Months Ended	12 Months Ended
		Jun. 30, 2017	Mar. 31, 2017
Opening Balance		$ 23,191,095	$ 263,906
Shares issued on acquisition (Note 3)			23,177,000
Options exercised			18,166
Warrants exercised		1,125,038	$ 40,195
Cashless exercise of warrants (iv) (in shares)			51,249
Cashless exercise of warrants (iv)			$ 43,562
Closing Balance		$ 22,526,649	$ 23,191,095
Exchangable Shares [Member]
Opening Balance (in shares)		47,909,336	50,000,000
Opening Balance		$ 47,910	$ 50,000
Converted into common shares (in shares)		0	(2,090,664)
Converted into common shares		$ 0	$ (2,090)
Closing Balance (in shares)		47,909,336	47,909,336
Closing Balance		$ 47,910	$ 47,910
Common Shares [Member]
Opening Balance (in shares)		48,885,107	22,591,292
Opening Balance		$ 48,884	$ 22,591
Shares issued on acquisition (Note 3)		$ 0	$ 23,650
Shares issued on acquisition (Note 3) (in shares)		0	23,650,000
Shares issued to exchangeable shareholders (in shares)		0	2,090,664
Shares issued to exchangeable shareholders		$ 0	$ 2,090
Shares issued for services (in shares)		0	217,047
Shares issued for services		$ 0	$ 217
Options exercised (in shares)		0	110,096
Options exercised		$ 0	$ 110
Warrants exercised	[1]	$ 5,000	$ 175
Warrants exercised (in shares)	[1]	5,000,172	174,759
Cashless exercise of warrants (iv) (in shares)		0	51,249
Cashless exercise of warrants (iv)		$ 0	$ 51
Closing Balance (in shares)		53,885,279	48,885,107
Closing Balance		$ 53,884	$ 48,884
Common Shares And Exchangeable Shares [Member]
Opening Balance (in shares)		96,794,443
Opening Balance		$ 96,794
Closing Balance (in shares)		101,794,615	96,794,443
Closing Balance		$ 101,794	$ 96,794
[1]	During the three month period ended June 30, 2017, the Company consummated an offer to amend and exercise to its warrant holders, enabling them to exercise their outstanding warrants for $0.25 per share, and as a result, 5,000,172 common shares were issued for net proceeds of $1,125,038. (Note 11)

SHARE CAPITAL (Details Textual)

SHARE CAPITAL (Details Textual) - USD ($)	1 Months Ended	3 Months Ended		12 Months Ended
	Feb. 25, 2015	Jun. 30, 2017	Jun. 30, 2016	Mar. 31, 2017
Share-based Compensation		$ 251,048	$ 219,248
Class of Warrant or Right, Exercise Price of Warrants or Rights		$ 0.25
Stock Issued During Period, Shares, Upon Cashless Exercise Of Warrants				51,249
Proceeds from Warrant Exercises		$ 1,125,038	$ 0
Investor Relation And Consultine Services [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights			$ 0.80
Stock Issued During Period, Shares, Upon Cashless Exercise Of Warrants			51,249
Number Of Warrants Exercised			262,045
Warrant [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights			$ 0.25
Stock Issued During Period, Shares, Warrants Exercised		5,000,172
Proceeds from Warrant Exercises		$ 1,125,038
Exchangable Shares [Member]
Stock Issued During Period, Shares, Issued for Services	262,904		70,000
Stock Issued During Period, Value, Issued for Services	$ 241,185		$ 59,500
Share-based Compensation	$ 210,323	$ 43,562

STOCK OPTIONS (Details)

STOCK OPTIONS (Details) - Employee Stock Option [Member]	3 Months Ended
	Jun. 30, 2017$ / sharesshares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Options	9,820,317
Number of Exercisable Options	6,362,689
Stock Option One [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price | $ / shares	$ 0.165
Number of Options	264,230
Expiry Date	Apr. 1, 2021
Number of Exercisable Options	264,230
Stock Option Two [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price | $ / shares	$ 0.23
Number of Options	97,514
Expiry Date	Jun. 20, 2021
Number of Exercisable Options	97,514
Stock Option Three [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price | $ / shares	$ 0.23
Number of Options	1,981,728
Expiry Date	Jul. 1, 2021
Number of Exercisable Options	1,981,728
Stock Option Four [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price | $ / shares	$ 0.23
Number of Options	204,471
Expiry Date	Feb. 17, 2022
Number of Exercisable Options	204,471
Stock Option Five [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price | $ / shares	$ 1.22
Number of Options	400,000
Expiry Date	Nov. 24, 2022
Number of Exercisable Options	133,333
Stock Option Six [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price | $ / shares	$ 1
Number of Options	2,316,667
Expiry Date	Dec. 14, 2022
Number of Exercisable Options	809,994
Stock Option Seven [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price | $ / shares	$ 0.95
Number of Options	111,937
Expiry Date	Mar. 28, 2023
Number of Exercisable Options	111,937
Stock Option Eight [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price | $ / shares	$ 1.05
Number of Options	433,027
Expiry Date	Mar. 28, 2023
Number of Exercisable Options	433,027
Stock Option Nine [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price | $ / shares	$ 1
Number of Options	250,000
Expiry Date	Apr. 26, 2023
Number of Exercisable Options	0
Stock Option Ten [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price | $ / shares	$ 1
Number of Options	750,000
Expiry Date	Aug. 8, 2023
Number of Exercisable Options	0
Stock Option Eleven [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price | $ / shares	$ 0.70
Number of Options	400,000
Expiry Date	Feb. 6, 2024
Number of Exercisable Options	0
Stock Option Twelve [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price | $ / shares	$ 0.68
Number of Options	250,000
Expiry Date	Feb. 13, 2024
Number of Exercisable Options	0
Stock Option Thirteen [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price | $ / shares	$ 0.95
Number of Options	31,620
Expiry Date	Mar. 3, 2024
Number of Exercisable Options	31,620
Stock Option Fourteen [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price | $ / shares	$ 1.05
Number of Options	122,324
Expiry Date	Mar. 3, 2024
Number of Exercisable Options	122,324
Stock Option Fifteen [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price | $ / shares	$ 0.95
Number of Options	15,810
Expiry Date	Mar. 14, 2024
Number of Exercisable Options	15,810
Stock Option Sixteen [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price | $ / shares	$ 1.05
Number of Options	61,162
Expiry Date	Mar. 14, 2024
Number of Exercisable Options	61,162
Stock Option Seventeen [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price | $ / shares	$ 0.95
Number of Options	82,213
Expiry Date	Sep. 30, 2024
Number of Exercisable Options	82,213
Stock Option Eighteen [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price | $ / shares	$ 1.05
Number of Options	318,042
Expiry Date	Sep. 30, 2024
Number of Exercisable Options	318,042
Stock Option Nineteen [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price | $ / shares	$ 0.95
Number of Options	7,431
Expiry Date	Jun. 2, 2025
Number of Exercisable Options	7,431
Stock Option Twenty [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price | $ / shares	$ 1.05
Number of Options	28,747
Expiry Date	Jun. 2, 2025
Number of Exercisable Options	28,747
Stock Option Twenty One [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price | $ / shares	$ 0.25
Number of Options	906,077
Expiry Date	Jul. 28, 2025
Number of Exercisable Options	906,077
Stock Option Twenty Two [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price | $ / shares	$ 0.95
Number of Options	671,859
Expiry Date	Jul. 29, 2025
Number of Exercisable Options	671,859
Stock Option Twenty Three [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price | $ / shares	$ 0.25
Number of Options	66,298
Expiry Date	Dec. 30, 2025
Number of Exercisable Options	53,909
Stock Option Twenty Four [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price | $ / shares	$ 0.95
Number of Options	49,160
Expiry Date	Dec. 30, 2025
Number of Exercisable Options	27,261

STOCK OPTIONS (Details Textual)

STOCK OPTIONS (Details Textual) - USD ($)

Feb. 06, 2017

Oct. 08, 2016

Aug. 08, 2016

Dec. 14, 2015

Feb. 13, 2017

Apr. 26, 2016

Apr. 21, 2016

Nov. 24, 2015

Feb. 26, 2015

Feb. 17, 2015

Jun. 30, 2017

Jun. 30, 2016

Dec. 31, 2014

Mar. 31, 2017

Mar. 31, 2016

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term

5 years 1 month 13 days

5 years 9 months 22 days

Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term

6 years 7 days

5 years 8 months 12 days

Employee Stock Option [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Allocated Share-based Compensation Expense

$ 251,048

$ 159,818

April issuance [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number

531,606

Share Based Compensation Arrangement By Share Based Payment Award Options Re-measured Fair value

$ 230,930

June issuance [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross

264,230

Allocated Share-based Compensation Expense

$ 118,957

Employees and Consultant [Member] | Employee Stock Option [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross

125,824

Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period

62,912

Employees and Consultant [Member] | April issuance [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross

657,430

Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price

$ 0.165

Employees and Consultant [Member] | June issuance [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross

264,230

Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price

$ 0.23

Management [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross

2,972,592

Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price

$ 0.23

Share Based Compensation Arrangement By Share Based Payment Award Options Issued Weighted Average Remaining Contractual Term1

7 years

Fair Value Of Options

$ 1,259,487

Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period

990,864

Director and Employees and Consultant [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price

$ 0.23

Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period

110,100

40,000

25,000

Allocated Share-based Compensation Expense

$ 100,289

Fair Value Of Options

$ 136,613

Employees of Bionik Inc [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price

$ 1

Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number

3,895,000

Allocated Share-based Compensation Expense

$ 17,813

Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period

250,000

3,000,000

Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value

$ 213,750

$ 2,582,890

Employees of Bionik Inc [Member] | Exercise Price Range One [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price

$ 0.25

Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period

1,000,000

Employees of Bionik Inc [Member] | Exercise Price Range Two [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price

$ 0.95

Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period

1,000,000

Employees of Bionik Inc [Member] | Exercise Price Range Three [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price

$ 1.05

Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period

1,000,000

Employees of Bionik Inc [Member] | Unvested option [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Allocated Share-based Compensation Expense

$ 10,169

Employees [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross

650,000

Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period

250,000

Allocated Share-based Compensation Expense

$ 35,609

Fair Value Of Options

$ 694,384

Employee One [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price

$ 1

Allocated Share-based Compensation Expense

$ 54,339

Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period

750,000

Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value

$ 652,068

Director and Employees and Consultant One [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross

2,495,000

314,560

Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period

83,334

Fair Value Of Options

$ 1,260,437

Employee Two [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price

$ 0.70

Allocated Share-based Compensation Expense

$ 20,433

Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period

400,000

Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value

$ 245,200

Consultant [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross

250,000

Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price

$ 0.68

Allocated Share-based Compensation Expense

$ 12,396

Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period

250,000

Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value

$ 148,750

WARRANTS (Details)

WARRANTS (Details) - $ / shares	3 Months Ended	12 Months Ended
	Jun. 30, 2017	Mar. 31, 2017	Mar. 31, 2016
Number of Warrants, Outstanding and exercisable, Beginning balance	17,638,243	17,900,288	10,823,450
Number of Warrants, Issued			7,225,625
Number of Warrants, Issued, Exercised	(5,000,172)	(262,045)	(148,787)
Number of Warrants, Outstanding and exercisable, Ending balance	13,663,014	17,638,243	17,900,288
Weighted-Average Exercise Price, Outstanding and exercisable, Beginning balance	$ 1.35	$ 1.35	$ 1.35
Weighted-Average Exercise Price, Issued			1.35
Weighted-Average Exercise Price, Exercised	0.25	(0.80)	(0.80)
Weighted-Average Exercise Price, Outstanding and exercisable, Ending balance	$ 1.241	$ 1.35	$ 1.35
Additional Warrants Issued One
Number of Warrants, Issued	83,752
Weighted-Average Exercise Price, Issued	$ 0.749
Additonal Warrant Issued Two
Number of Warrants, Issued	941,191
Weighted-Average Exercise Price, Issued	$ 1.2933

WARRANTS (Details 1)

WARRANTS (Details 1) - $ / shares	3 Months Ended
	Jun. 30, 2017	Mar. 31, 2017
Class of Warrant or Right [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 0.25
Class of Warrant or Right, Number of Warrants	13,663,014
Warrant One [Member]
Class of Warrant or Right [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 1.2933
Class of Warrant or Right, Number of Warrants	5,873,289	7,735,750
Class Of Warrant Or Right Expiry Date	Feb. 26, 2019
Warrant Three [Member]
Class of Warrant or Right [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 1.2933
Class of Warrant or Right, Number of Warrants	1,229,040	1,212,500
Class Of Warrant Or Right Expiry Date	Mar. 27, 2019
Warrant Five [Member]
Class of Warrant or Right [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 1.2933
Class of Warrant or Right, Number of Warrants	328,166	891,250
Class Of Warrant Or Right Expiry Date	Mar. 31, 2019
Warrant Seven [Member]
Class of Warrant or Right [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 1.2933
Class of Warrant or Right, Number of Warrants	2,544,240	3,115,000
Class Of Warrant Or Right Expiry Date	Apr. 21, 2019
Warrant Nine [Member]
Class of Warrant or Right [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 1.2933
Class of Warrant or Right, Number of Warrants	1,201,164	1,418,750
Class Of Warrant Or Right Expiry Date	May 27, 2019
Warrant Eleven [Member]
Class of Warrant or Right [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 1.2933
Class of Warrant or Right, Number of Warrants	1,173,370	2,035,000
Class Of Warrant Or Right Expiry Date	Jun. 30, 2019
Classes Of Warrants Two [Member]
Class of Warrant or Right [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 0.7490
Class of Warrant or Right, Number of Warrants	1,313,745	1,229,993
Class Of Warrant Or Right Expiry Date	Feb. 26, 2019

WARRANTS (Details 2)

WARRANTS (Details 2) - USD ($)	3 Months Ended		12 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Mar. 31, 2017	Mar. 31, 2016	Mar. 31, 2015
Derivative Liability, Fair Value, Gross Liability	$ 959,600	$ 5,135,990	$ 5,135,990	$ 8,382,648
Change in fair value of warrant derivative liability	4,804	$ 391,059	(4,176,390)	(8,290,556)	$ 6,036,659
Fair value of warrants exercised	$ (204,790)			(60,966)
Class of Warrant or Right, Outstanding	13,663,014
Derivative Liability, Fair Value, Gross Liability	$ 759,714		$ 959,600	$ 5,135,990	$ 8,382,648
Warrants Issued In February 26, 2015 Financing [Member]
Class of Warrant or Right, Outstanding				8,509,325
Derivative Liability, Fair Value, Gross Liability				$ 550,374
Class of Warrant or Right, Outstanding					8,509,325
Derivative Liability, Fair Value, Gross Liability					$ 550,374
Warrants Issued In March 27, 2015 Financing [Member]
Class of Warrant or Right, Outstanding				1,333,750
Derivative Liability, Fair Value, Gross Liability				$ 1,036,325
Class of Warrant or Right, Outstanding					1,333,750
Derivative Liability, Fair Value, Gross Liability					$ 1,036,325
Warrants Issued In March 31, 2015 Financing [Member]
Class of Warrant or Right, Outstanding				980,375
Derivative Liability, Fair Value, Gross Liability				$ 759,290
Class of Warrant or Right, Outstanding					980,375
Derivative Liability, Fair Value, Gross Liability					$ 759,290
Warrants Issued In April 21, 2015 Financing [Member]
Class of Warrant or Right, Outstanding				3,426,500
Derivative Liability, Fair Value, Gross Liability				$ 2,588,722
Class of Warrant or Right, Outstanding					3,426,500
Derivative Liability, Fair Value, Gross Liability					$ 2,588,722
Warrants Issued In May 27, 2015 Financing [Member]
Class of Warrant or Right, Outstanding				1,560,625
Derivative Liability, Fair Value, Gross Liability				$ 1,025,173
Class of Warrant or Right, Outstanding					1,560,625
Derivative Liability, Fair Value, Gross Liability					$ 1,025,173
Warrants Issued In June 30, 2015 Financing [Member]
Class of Warrant or Right, Outstanding				2,238,500
Derivative Liability, Fair Value, Gross Liability				$ 1,490,969
Class of Warrant or Right, Outstanding					2,238,500
Derivative Liability, Fair Value, Gross Liability					$ 1,490,969

WARRANTS (Details 3)

WARRANTS (Details 3) - USD ($)	3 Months Ended	12 Months Ended
	Jun. 30, 2017	Mar. 31, 2017
Number of Warrants	13,663,014
Warrant One [Member]
Number of Warrants	5,873,289	7,735,750
Expected life in years		4 years
Exercise Price		$ 1.40
Risk free rate		0.44%
Dividend rate		0.00%
Expected volatility		51.83%
Fair value		$ 464,784
Warrant Two [Member]
Number of Warrants		773,575
Expected life in years		4 years
Exercise Price		$ 0.80
Risk free rate		0.44%
Dividend rate		0.00%
Expected volatility		51.83%
Fair value		$ 85,590
Warrant Three [Member]
Number of Warrants	1,229,040	1,212,500
Expected life in years		3 years 11 months 1 day
Exercise Price		$ 1.40
Risk free rate		0.43%
Dividend rate		0.00%
Expected volatility		52.37%
Fair value		$ 950,913
Warrant Four [Member]
Number of Warrants		121,250
Expected life in years		3 years 11 months 1 day
Exercise Price		$ 0.80
Risk free rate		0.43%
Dividend rate		0.00%
Expected volatility		52.37%
Fair value		$ 85,412
Warrant Five [Member]
Number of Warrants	328,166	891,250
Expected life in years		3 years 10 months 28 days
Exercise Price		$ 1.40
Risk free rate		0.41%
Dividend rate		0.00%
Expected volatility		52.45%
Fair value		$ 696,582
Warrant Six [Member]
Number of Warrants		89,125
Expected life in years		3 years 10 months 28 days
Exercise Price		$ 0.80
Risk free rate		0.41%
Dividend rate		0.00%
Expected volatility		52.45%
Fair value		$ 62,708
Warrant Seven [Member]
Number of Warrants	2,544,240	3,115,000
Expected life in years		3 years 10 months 6 days
Exercise Price		$ 1.40
Risk free rate		0.68%
Dividend rate		0.00%
Expected volatility		51.54%
Fair value		$ 2,371,956
Warrant Eight [Member]
Number of Warrants		311,500
Expected life in years		3 years 10 months 6 days
Exercise Price		$ 0.80
Risk free rate		0.68%
Dividend rate		0.00%
Expected volatility		51.54%
Fair value		$ 216,766
Warrant Nine [Member]
Number of Warrants	1,201,164	1,418,750
Expected life in years		3 years 9 months 4 days
Exercise Price		$ 1.40
Risk free rate		0.46%
Dividend rate		0.00%
Expected volatility		51.74%
Fair value		$ 933,065
Warrant Ten [Member]
Number of Warrants		141,875
Expected life in years		3 years 9 months 4 days
Exercise Price		$ 0.80
Risk free rate		0.46%
Dividend rate		0.00%
Expected volatility		51.74%
Fair value		$ 92,108
Warrant Eleven [Member]
Number of Warrants	1,173,370	2,035,000
Expected life in years		3 years 7 months 28 days
Exercise Price		$ 1.40
Risk free rate		0.37%
Dividend rate		0.00%
Expected volatility		52.94%
Fair value		$ 1,356,512
Warrant Twelve [Member]
Number of Warrants		203,500
Expected life in years		3 years 7 months 28 days
Exercise Price		$ 0.80
Risk free rate		0.37%
Dividend rate		0.00%
Expected volatility		52.94%
Fair value		$ 134,457
Classes of Warrants 1 [Member]
Number of Warrants	12,349,269	16,408,250
Expected life in years	1 year 10 months 28 days	1 year 10 months 28 days
Exercise Price	$ 1.2933	$ 1.40
Risk free rate	0.65%	0.65%
Dividend rate	0.00%	0.00%
Expected volatility	53.58%	53.58%
Fair value	$ 667,184	$ 849,713
Classes Of Warrants 2 [Member]
Number of Warrants	1,313,745	1,229,993
Expected life in years	1 year 10 months 28 days	1 year 10 months 28 days
Exercise Price	$ 0.7490	$ 0.80
Risk free rate	0.65%	0.65%
Dividend rate	0.00%	0.00%
Expected volatility	53.58%	53.58%
Fair value	$ 92,530	$ 109,887

WARRANTS (Details Textual)

WARRANTS (Details Textual) - USD ($)	3 Months Ended			12 Months Ended
	Jun. 30, 2017	Mar. 31, 2017	Jun. 30, 2016	Mar. 31, 2017	Mar. 31, 2016
Class of Warrant or Right [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 0.25
Derivative, Gain on Derivative	$ 4,804		$ 391,059
Warrant Redemption Terms	The Company has the option to redeem the warrants for $0.001 per warrant if the daily volume weighted-average price of the common shares is 200% or more of the exercise price for twenty consecutive trading days provided there is an effective registration statement covering the shares of common stock available throughout the thirty day period after the redemption date. The warrant holders then have thirty days to exercise the warrants or receive the redemption amount.
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumption, Holding Cost Percentage	2.25%
Daily Volume Weighted Average Share Price Minimum Threshold Percentage	200.00%
Stock Issued During Period, Shares, Upon Cashless Exercise Of Warrants				51,249
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms	1 year 6 months 7 days	1 year 9 months 7 days
Number Of Warrants Exercised	5,000,172			262,045	148,787
Share Based Compensaction Arrangement By Share Based Payment Award Non Options Exercised Weighted Average Exercise Price	$ (0.25)			$ 0.80	$ 0.80
Proceeds from Warrant Exercises	$ 1,125,038		$ 0
Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Granted					7,225,625
$0.80
Class of Warrant or Right [Line Items]
Share Based Compensaction Arrangement By Share Based Payment Award Non Options Exercised Weighted Average Exercise Price	$ 0.7490
Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Granted	83,752
Warrant $0.80 | Scenario, Previously Reported [Member]
Class of Warrant or Right [Line Items]
Share Based Compensaction Arrangement By Share Based Payment Award Non Options Exercised Weighted Average Exercise Price	$ 0.80
$1.40
Class of Warrant or Right [Line Items]
Share Based Compensaction Arrangement By Share Based Payment Award Non Options Exercised Weighted Average Exercise Price	$ 1.2933
Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Granted	941,191
Warrant $1.40 | Scenario, Previously Reported [Member]
Class of Warrant or Right [Line Items]
Share Based Compensaction Arrangement By Share Based Payment Award Non Options Exercised Weighted Average Exercise Price	$ 1.40
Common Shares [Member]
Class of Warrant or Right [Line Items]
Stock Issued During Period, Shares, Upon Cashless Exercise Of Warrants					45,508
Number Of Warrants Exercised					148,787
Warrant [Member]
Class of Warrant or Right [Line Items]
Proceeds from Warrant Exercises	$ 1,129,193

COMMITMENTS AND CONTINGENCIES (

COMMITMENTS AND CONTINGENCIES (Details Textual) - USD ($)	1 Months Ended	3 Months Ended
	Feb. 25, 2015	Jun. 30, 2017	Jun. 30, 2016
Share-based Compensation		$ 251,048	$ 219,248
Exchangable Shares [Member]
Stock Issued During Period, Shares, Issued for Services	262,904		70,000
Stock Transferred To Lenders	314,560
Stock Reimbursed To Officers	320,000
Stock Issued During Period, Value, Issued for Services	$ 241,185		$ 59,500
Share-based Compensation	$ 210,323	$ 43,562

RISK MANAGEMENT (Details Textua

RISK MANAGEMENT (Details Textual)	Jun. 30, 2016CAD
Maximum [Member]
Concentration Risk [Line Items]
Cash, FDIC Insured Amount	CAD 100,000

SUBSEQUENT EVENTS (Details Text

SUBSEQUENT EVENTS (Details Textual)	3 Months Ended
	Jun. 30, 2017shares
Consultant [Member]
Subsequent Event [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	250,000
Executive Employee [Member]
Subsequent Event [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	1,500,000
Share Based Compensation Arrangement By Share Based Payment Award Additional Options Grants In Period Gross	500,000